Not exactly took off so far I'm guessing the recent rise accounts for some of it |
Sone peeps knew this was in the works....
700k worked buy yesterday. |
Illumina customer that is |
Just do the maths. If every Illumina bought a machine!! Or give them machines free and the just used one slide a day!!This is all we need tbh. Forget the rest |
Wonderful news.I'll set out my theory again.NHS testing just started with liquid biopsies.CtDNA testing offers better insight and Parsotix adopted.AZ make offer for the Company. |
Good rns I just get the feeling it's one that means it's down the line again and they have to get there first . Lots of talking and presentations but no actual revenues from it for a couple of years so will be interesting from seeing how the share price reacts .
Will it be another spike and fall back as the next fund raise gets closer . Positive at least just seems always more time to wait with agl |
Liquid biopsy analytes including circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) represent important minimally invasive biomarker sources for molecular profiling as a step towards realizing precision oncology.
In this webinar, Anne-Sophie Pailhes-Jimenez will present dual analysis data from samples taken from lung cancer patients using Parsortix system by ANGLE. Targeted next-generation sequencing (NGS) on the NextSeq 2000 sequencer was performed and revealed mutations identified exclusively on CTCs compared to cfDNA. Overall, dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care
Format:
A 60-minute webinar with plenty of time for participants to submit typed questions. Participants will not be visible but will have the opportunity to use their microphones to ask questions verbally if they choose to. |
Well if Illumina get behind AGL then it huge.. But I guess a way to go... Happy with the RNS though.. |
Not an RNS Reach either, clearly the company thinks this is significant. |
Amongst similar RNS's..this one looks pretty significant... |
This rns should surely confirm the break above the 200 day moving average. |
Havingthelasttoast.......I know where I'd like to place you. |
Placing anyone ? |
The NHS testing news is very positive for ANGLE as we know from studies the ctDNA material in their test does not provide insights critical for a full understanding of cancer's behaviour.To do improve the test it would require CTCs to be analysed and the use of Parsotix. Hopefully more news soon |
Today could see confirmation of breakout above 200 day MA
free stock charts from uk.advfn.com |
https://www.proactiveinvestors.com.au/companies/news/1065008/angle-plc-says-nature-medicine-journal-highlights-parsortix-s-role-in-cancer-breakthrough-1065008.html |
Note the GH test will cost the NHS £750, two labs doing it, the parsortix test on top might be more than that, one problem will be resources should the AGL test be adopted, it's so labour-intensive and fiddly with meticulous attention required to prevent cross-contamination between samples. |
Certainly a lot of possibilities. |
c3479z1
I agree with you but first they need to find a drug therapy or should I say the correct drug therapy which would work on the cells they’ve captured in post-op Metastatic patients.
They won’t do six or 12 months tests post op in all women unless they know how to treat it when they find it. |
would have thought the nature medicine study should indicate that Parsortix could be most useful for monitoring post-op in women without evidence of metastatic disease especially those at higher risk for metastases, rather than in the metastatic setting where the existence of tumour cell clusters adds little value except to guide drug therapy. There again, even seemingly low risk patients can develop metastatic disease; the survival curves continue to diverge for 30 or more years in breast cancer compared with non-sufferers. Late metastasis/scar recurrence 15 years or more post surgery is not that uncommon. Begs the question of where the cells have been all that time? some suggest micrometastases/isolated tumour cells lie dormant in the bone marrow and are reactivated by some unknown trigger.
So, Parsortix could find a role in all women post-op without evidence of metastatic disease for monitoring. problem is cash burn. |
https://www.proactiveinvestors.com.au/companies/news/1065008/angle-plc-says-nature-medicine-journal-highlights-parsortix-s-role-in-cancer-breakthrough-1065008.html |
Building up momentum for a confirmed* breakout of the 200 day MA
free stock charts from uk.advfn.com
* Usually technical analysts will look for secondary indicator clues as to strength and conviction of breakout such as volume, 2 consecutive days close above the level and a retest of resistance as support |
Imagine bones walking along the pavement and kicking cats in the belly when no one is looking. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
